EU Innovative Health Initiative
Takeda’s zasocitinib shows high rates of skin clearance in phase 3 psoriasis studies
Globally, an estimated 64 million people have psoriasis, with about 80-90% of those having plaque psoriasis
Takeda’s new study data for oveporexton shows improvements in narcolepsy type 1
The phase 3 results show improvements in daily function, cognition and nighttime sleep
Boehringer Ingelheim and Simcere announce inflammatory bowel disease collaboration
There are more than three million people affected by IBD globally, with a need to improve current treatments
Takeda’s zasocitinib demonstrates positive results in plaque psoriasis
Around 64 million people worldwide live with psoriasis
BMS, Takeda and Astex join AI training consortium
The initiative focuses on training AI models to aid in drug discovery and development
Abivax shares positive late-stage results for obefazimod in ulcerative colitis
Inflammatory bowel disease affects nearly one in every 100 people in the US
Takeda receives EC approval for Adcetris combination in Hodgkin lymphoma
The decision marks the second approval for an Adcetris-based regimen for front-line Hodgkin lymphoma
Takeda’s Adzynma approved by MHRA for rare blood clotting disorder cTTP
The enzyme replacement therapy is now the first treatment approved in the UK for this patient population
Johnson & Johnson shares long-term results for Tremfya in ulcerative colitis
More than 2.5 million people in Europe are affected by the inflammatory bowel disease
Takeda receives CHMP recommendation for Adcetris in Hodgkin lymphoma
The EC will review the committee’s positive opinion as it makes a decision on Adcetris in this indication
J&J’s Stelara granted EC approval to treat Crohn’s disease in paediatric patients
Approximately 25% of cases are diagnosed during childhood or adolescence
Takeda receives NICE recommendation for Adcetris combination in Hodgkin lymphoma
Around 800 people in the UK are diagnosed with late-stage disease every year